楚天科技股份有限公司 2025 年第三季度报告 1.董事会及董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担 个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 □是 否 1 | 证券代码：300358 证券简称：楚天科技 | 公告编号：2025-061 号 | | --- | --- | | 债券代码：123240 债券简称：楚天转债 | | 楚天科技股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 楚天科技股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末比上 年初至报告期末 | | | --- | --- | --- | --- | --- | | | | 增减 | 年同期增减 | ...

Core Viewpoint - The company, Chutian Technology, has committed to transparently disclosing its operational status in accordance with relevant standards and regulations, while also enhancing its value promotion and management capabilities to protect investor interests [2] Group 1 - Chutian Technology responded to investor inquiries on October 24, indicating its adherence to disclosure requirements [2] - The company plans to further improve its value communication and management skills [2] - The focus is on maintaining the interests of a broad base of investors [2]

Core Viewpoint - Chutian Technology (300358) is enhancing contract quality management, cost control, and delivery efficiency to improve the gross margin of its various products [1] Group 1 - The company is focusing on strengthening contract quality management [1] - The company is implementing measures to enhance cost control [1] - The company aims to improve delivery efficiency [1] - The company is continuously working to increase the gross margin of its products [1]

Group 1 - The core point of the article is that Chutian Technology is collaborating with Heyuan Biotechnology to provide solutions for the large-scale production of a globally innovative "rice-derived" product [2] - Chutian Technology confirmed on the investor interaction platform that Heyuan Biotechnology is one of its clients, and they are assisting in the establishment of the world's first plant-derived recombinant human albumin injection production line [2] - Chutian Technology's subsidiary, Chutian Yuanchuang, is supplying several sets of fully automated chromatography columns and associated online liquid chromatography systems, as well as multiple ultrafiltration systems for the project [2]

Core Insights - On October 22, Chutian Technology experienced a decline of 2.53% with a trading volume of 177 million yuan, indicating a negative market sentiment towards the company [1] - The company reported a net financing outflow of 503.73 million yuan on the same day, suggesting a higher level of selling pressure compared to buying [1] - As of October 22, the total margin balance for Chutian Technology stood at 233 million yuan, which is 4.49% of its market capitalization, indicating a high level of margin activity [1] Financing and Margin Trading - On October 22, Chutian Technology had a financing buy-in amount of 15.22 million yuan, while the financing repayment was 20.26 million yuan, leading to a net financing buy of -5.04 million yuan [1] - The current financing balance of 233 million yuan exceeds the 90th percentile of the past year, indicating a high level of leverage [1] - In terms of securities lending, the company repaid 500 shares and sold 1,300 shares on October 22, with a selling amount of 11,500 yuan, reflecting active short-selling [1] Company Overview - Chutian Technology, established on November 8, 2002, and listed on January 21, 2014, is based in Ningxiang, Hunan Province, and specializes in pharmaceutical equipment and comprehensive technical solutions [2] - The company's revenue composition includes: detection packaging solutions (24.88%), accessories and after-sales services (16.44%), and various other solutions, with the total revenue for the first half of 2025 being 2.417 billion yuan, a year-on-year decrease of 14.55% [2] - The net profit attributable to shareholders for the same period was -12.30 million yuan, but this represents an 85.11% year-on-year improvement [2] Shareholder and Dividend Information - Since its A-share listing, Chutian Technology has distributed a total of 361 million yuan in dividends, with 117 million yuan distributed over the last three years [3] - As of June 30, 2025, the number of shareholders increased by 3.48% to 27,800, while the average circulating shares per person decreased by 3.35% to 20,731 shares [2][3] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 10.19 million shares, an increase of 3.45 million shares from the previous period [3]

Core Insights - Chutian Technology's stock price increased by 2.02% on October 16, reaching 9.58 CNY per share, with a market capitalization of 5.655 billion CNY [1] - The company has seen a year-to-date stock price increase of 39.65%, with a 2.46% rise in the last five trading days [1] Financial Performance - For the first half of 2025, Chutian Technology reported revenue of 2.417 billion CNY, a year-on-year decrease of 14.55%, while the net profit attributable to shareholders was -12.3046 million CNY, an increase of 85.11% year-on-year [2] - Cumulative cash dividends since the company's A-share listing amount to 361 million CNY, with 117 million CNY distributed over the last three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 3.48% to 27,800, with an average of 20,731 circulating shares per shareholder, a decrease of 3.35% [2] - The top three circulating shareholders include Hong Kong Central Clearing Limited, holding 10.1871 million shares, an increase of 3.4465 million shares from the previous period [3] Business Overview - Chutian Technology, established on November 8, 2002, and listed on January 21, 2014, specializes in pharmaceutical equipment and comprehensive technical solutions [1] - The company's revenue composition includes: 24.88% from testing and packaging solutions, 16.44% from parts and after-sales services, and 14.84% from biotechnology solutions, among others [1] Industry Classification - Chutian Technology is classified under the pharmaceutical and biological industry, specifically in medical devices and equipment [2] - The company is associated with several concepts, including Industry 4.0, financing and securities lending, robotics, food and drug traceability, and DeepSeek concepts [2]

Group 1 - The core viewpoint of the news highlights the recent stock performance and financial metrics of Chutian Technology, indicating a significant increase in stock price and fluctuations in trading volume [1][2]. - As of October 15, Chutian Technology's stock price rose by 2.09% to 9.29 CNY per share, with a total market capitalization of 5.484 billion CNY [1]. - The company has experienced a year-to-date stock price increase of 35.42%, with notable gains over various trading periods: 5.57% in the last 5 days, 13.43% in the last 20 days, and 15.12% in the last 60 days [1]. Group 2 - For the first half of 2025, Chutian Technology reported a revenue of 2.417 billion CNY, reflecting a year-on-year decrease of 14.55%, while the net profit attributable to shareholders was -12.3046 million CNY, showing an 85.11% increase compared to the previous period [2]. - The company has distributed a total of 361 million CNY in dividends since its A-share listing, with 117 million CNY distributed over the past three years [3]. - As of June 30, 2025, the number of shareholders increased by 3.48% to 27,800, while the average circulating shares per person decreased by 3.35% to 20,731 shares [2][3].

| 证券代码：300358 | 证券简称：楚天科技 | 公告编号：2025-058 号 | | --- | --- | --- | | 债券代码：123240 | 债券简称：楚天转债 | | 楚天科技股份有限公司 关于 2025 年第三季度可转换公司债券转股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、楚天转债（债券代码：123240）转股期限为 2024 年 8 月 6 日至 2030 年 1 月 30 日，最新有效的转股价格为人民币 8.00 元/股。 2、2025 年第三季度，共有 39 张"楚天转债"完成转股（票面金额 3900 元 人民币），转换成"楚天科技"股票 487 股。 3、截至 2025 年第三季度末，楚天科技股份有限公司（以下简称"公司"） 剩余可转换公司债券（以下简称"可转债"）为 9,999,771 张，剩余票面总金额 为 99,997.71 万元人民币。 根据《深圳证券交易所创业板股票上市规则》和《深圳证券交易所上市公司 自律监管指引第 15 号——可转换公司债券》的有关规定，公司现将 2025 年第三 ...

Core Points - The company announced the convening of the sixth board meeting on August 26, 2025, to review the proposal for expanding its business scope and revising the articles of association [1] - The company plans to reduce the number of board members from 14 to 13 [1] - The company has completed the necessary business registration changes and obtained a new business license from the Changsha Market Supervision Administration [1]

Core Points - The company held its sixth board meeting on August 26, 2025, where it approved the expansion of its business scope and amendments to the Articles of Association [1] - The first extraordinary shareholders' meeting of 2025 on September 15 also approved the same proposals [1] - The company has reduced the number of board members from 14 to 13 and made corresponding amendments to the Articles of Association [1] - The company has completed the necessary procedures for business registration changes and has obtained a new business license from the Changsha Market Supervision Administration [1]